Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada
RYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray) treats moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms
Read MoreRYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray) treats moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms
Read MoreRYALTRIS™ is the only fixed-dose combination therapy that provides relief for both nasal and ocular symptoms of seasonal allergic rhinitis
Read MoreUnder the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris™, while Lotus International
Read More– Ryaltris™ is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray approved by the FDA for the treatment
Read More